Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/12/16 18:49:03」(JST)
[Wiki en表示]
Ulobetasol
|
Systematic (IUPAC) name |
(6α,11β,16β)-21-chloro-6,9-difluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione |
Clinical data |
AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
MedlinePlus |
a601060 |
Legal status |
?
|
Identifiers |
CAS number |
98651-66-2 N |
ATC code |
D07AC21 |
PubChem |
CID 5311167 |
ChemSpider |
4470691 Y |
UNII |
9P6159HM7T Y |
KEGG |
D08660 Y |
ChEMBL |
CHEMBL1201360 N |
Synonyms |
(6S,8S,9S,10S,11S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one |
Chemical data |
Formula |
C22H27ClF2O4 |
Mol. mass |
428.897 |
SMILES
- ClCC(=O)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@@H]3C)C)C
|
InChI
-
InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1 Y
Key:LEHFPXVYPMWYQD-XHIJKXOTSA-N Y
|
N (what is this?) (verify) |
Ulobetasol (or halobetasol) is a corticosteroid used to treat psoriasis. It is a group I corticosteroid under the US classification, the most potent class of such drugs. Halobetasol propionate is usually supplied as a 0.05% topical cream.
External links
- halobetasol at the US National Library of Medicine Medical Subject Headings (MeSH)
Corticosteroids – glucocorticoids and mineralocorticoids (H02)
(also A07EA, C05AA, D07, D10AA, R01AD, R03BA, S01BA, S02B, and S03B)
|
|
Mineralocorticoids
(3-one, 4-ene,
no FG at 16) |
- Pregnenedione: ALDOSTERONE
- 11-DEOXYCORTICOSTERONE
- HALOGENATED AT 9: Fludrocortisone
|
|
Glucocorticoids
(3-one, 4-ene,
11-FG,
17-hydroxy) |
Pregnene
|
|
|
Pregnenedione
(+20-one)
|
- HYDROCORTISONE/CORTISOL# (Hydrocortisone aceponate
- Hydrocortisone buteprate
- Hydrocortisone butyrate)
- Budesonide
- Ciclesonide
- Deflazacort
- Medrysone
- Tixocortol
- HALOGENATED AT 6: Cloprednol
- HALOGENATED, WITH FG AT 16: Halcinonide
|
|
Pregnadiene (+1-ene)
|
- Rimexolone
- HALOGENATED, WITH FG AT 16: Flunisolide
- Triamcinolone
- Amcinonide
- Fluocinolone acetonide (Fluocinonide)
|
|
Pregnadienediol
(+21-hydroxy)
|
- Prednisone (Meprednisone)
- HALOGENATED AT 9: Fluorometholone
- HALOGENATED, WITH FG AT 16: Fluocortolone (Clocortolone
- Diflucortolone
- Fluocortin)
- Desoximetasone
|
|
Pregnadienetriol
(+11-hydroxy)
|
- Prednisolone# (Methylprednisolone
- Methylprednisolone aceponate
- Prednicarbate
- Prednylidene)
- Desonide
- HALOGENATED: Fluprednisolone (Difluprednate
- Fluperolone)
- HALOGENATED, WITH FG AT 16: Dexamethasone#
- Betamethasone (Clobetasol
- Clobetasone
- Diflorasone
- Halometasone
- Ulobetasol)
- Beclometasone
- Paramethasone
- Alclometasone
- Fluclorolone acetonide
- Flumetasone
- Fluprednidene
|
|
Pregnatriene
(+2-ene)
|
|
|
Androstene
|
- HALOGENATED, WITH FG AT 16: Fluticasone (Fluticasone propionate
- Fluticasone furoate)
|
|
Other/ungrouped
|
- HALOGENATED: Loteprednol
- HALOGENATED, WITH FG AT 16: Fludroxycortide
- Formocortal
- Mometasone furoate
|
|
|
Aldosterone antagonists |
- Spironolactone
- Eplerenone
- Potassium canrenoate
- Canrenone
|
|
Synthesis modifiers |
- Trilostane
- Carbenoxolone
- Aminoglutethimide
- Metyrapone
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
|
noco (d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H2/H3/H5)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Impurity profiling and a stability-indicating UPLC method development and validation for the estimation of related impurities of halobetasol propionate in halobetasol propionate 0.05% (w/w) cream.
- Prakash L1, Malipeddi H2, Subbaiah BV3, Lakka NS3.
- Journal of chromatographic science.J Chromatogr Sci.2015 Jan;53(1):112-21. doi: 10.1093/chromsci/bmu027. Epub 2014 May 2.
- A simple, short and stability-indicating reverse phase-ultra-performance liquid chromatography method was developed and validated for the quantitative determination of related impurities of halobetasol propionate in halobetasol propionate 0.05% cream formulation. The proposed method was developed on
- PMID 24795078
- Quantification of halobetasol propionate and its impurities present in topical dosage forms by stability-indicating LC method.
- Nalwade S1, Reddy VR2, Kulkarni D3, Todamal S3.
- Journal of chromatographic science.J Chromatogr Sci.2015 Jan;53(1):127-34. doi: 10.1093/chromsci/bmu029. Epub 2014 Apr 30.
- A novel, sensitive, stability-indicating, gradient, reverse-phase high-performance liquid chromatographic method has been developed for quantitative determination of halobetasol propionate and its impurities in topical dosage forms. The chromatographic separation was achieved on a Phenomenex Synergi
- PMID 24784115
- An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis.
- Czarnowicki T1, Linkner RV2, Suárez-Fariñas M3, Ingber A4, Lebwohl M2.
- Journal of the American Academy of Dermatology.J Am Acad Dermatol.2014 Nov;71(5):954-959.e1. doi: 10.1016/j.jaad.2014.05.040. Epub 2014 Jun 11.
- BACKGROUND: Topical corticosteroids are the most common first-line treatment for psoriasis. Tachyphylaxis, a decreased response to treatment with repetitive application of the drug, is a controversial phenomenon associated with topical corticosteroid treatment.OBJECTIVE: We sought to prove or dispro
- PMID 24929883
Related Links
- Physician reviewed halobetasol topical patient information - includes halobetasol topical description, dosage and directions.
★リンクテーブル★
[★]
- 関
- halobetasol propionate
[★]
ハロベタソール
- 関
- ulobetasol